Roche

Roche is the 5th largest pharmaceutical company in the world, based on annual sales, which were recorded at $36,017m in 2009. The pharmaceutical products of Roche are major players in the followin...

EPO rDNA Roche

Digoxin Globulin ovine Fab Roche

Interleukin-2 receptor Mab rDNA Roche

macitentan

Macitentan (Opsumit®) is a novel dual endothelin receptor antagonist (ERA) that resulted from a tailored drug discovery process with the target to develop an ERA optimized for efficacy and safet...

Mircera methoxy polyethylene glycol-epoetin beta regulatory update

Partnering with Roche: Think Roche, Think Partnering

Roche is a top pharma company active in partnering, licensing and M&A in pharmaceuticals and biotechology. Roche has an active partnering group that recognizes the significant role played by 3rd p...

Chugai's Mircera Sales Down At ¥7.5 billion, No Change To Annual Forecast

Chugai Pharmaceuticals announced its financial figures for the second quarter July 26.

Human medicines European Public Assessment Report (EPAR): Mircera, methoxy polyethylene glycol-epoetin beta, Revision: 13, Authorised

Human medicines European Public Assessment Report (EPAR): Mircera, methoxy polyethylene glycol-epoetin beta, Revision: 12, Authorised

Roche sees strong 2012 performance in USA but slowdown in Europe

Swiss drug major Roche (ROG: SIX) has reported 2012 financial results with 4% growth in group sales to 45.5 billion Swiss francs ($49.29 billion), slightly more than analysts expectations of 45.3 bill...

Eight of Top 20 Drugs in Sales are Biologics

This from The Cell Culture Dish (via GEN) shows the Top 8 biologic drugs in 2012. They ranged from $4.0 B to $9.26 B, and all grew in sales in 2012. The stats appear below: Humira $9.26 B AbbVie Remic...

Commerce Resources Corp. Engages Roche Ltd. for the Ashram Rare Earth Element Deposit Pre-Feasibility Study

VANCOUVER, Sept. 21, 2012 /PRNewswire/ - Commerce Resources Corp. (TSXv: CCE; FSE: D7H; OTCQX: CMRZF) (the "Company") is pleased to announce that it has engaged Roche Ltd. (Roche) to complete a Pr...

Recent developments in doping testing for erythropoietin.

The constant development of new erythropoiesis-stimulating agents (ESAs), since the first introduction of recombinant erythropoietin (rhEpo) for clinical use, has also necessitated constant developmen...

Evaluation of the interference of hemoglobin, bilirubin, and lipids on Roche Cobas 6000 assays.

Pre-analytical error accounts for major total laboratory errors. We assessed the impacts of hemolysis, icterus, and lipemia on laboratory tests on Roche Cobas 6000.

4-Substituted-7-N-alkyl-N-acetyl 2-aminobenzothiazole amides: drug-like and non-xanthine based A2B adenosine receptor antagonists.

7-N-Acetamide-4-methoxy-2-aminobenzothiazole 4-fluorobenzamide (compound 1) was chosen as a drug-like and non-xanthine based starting point for the discovery of A(2B) receptor antagonists because of i...

Glycine Transporter (GlyT1) Inhibitors with Reduced Residence Time Increase Prepulse Inhibition without Inducing Hyperlocomotion in DBA/2 Mice.

Inhibition of the glycine transporter type 1 (GlyT1) leading to potentiation of the glycine site (GlyB) on the N-methyl-d-aspartate (NMDA) receptor has been proposed as a novel therapeutic approach fo...

Selective antagonists of mouse trace amine-associated receptor 1 (mTAAR1): Discovery of EPPTB (RO5212773).

High throughput screening of the Roche compound library identified benzanilides such as 1 and 2 as antagonists of TAAR1. Optimisation of this hit series led to the first selective TAAR1 antagonist (N-...